Deal Corner
May 01, 2012
India Venture Trust - Fund I, a scheme of IndiaVenture Trust subscribed to compulsorily convertible preference shares of Vardhman Chemtech Limited for INR 700 million

DEAL BRIEF

India Venture Trust - Fund I, a scheme of IndiaVenture Trust ("IndiaVenture") subscribed to compulsorily convertible preference shares of Vardhman Chemtech Limited for INR 700 million (~USD 14 million).

Vardhman Chemtech Limited is engaged in the business of manufacturing of bulk drugs, intermediates & fine chemicals in the isoxazoles segment of penicillin.

OUR ROLE

We, at Nishith Desai Associates, acted as legal counsel to IndiaVenture Trust for this Transaction.

Disclaimer

The contents of this hotline should not be construed as legal opinion. View detailed disclaimer.

We expressly clarify that this communication is not a solicitation or an invitation of any sort whatsoever from Nishith Desai Associates or any of its members to create an attorney-client relationship. This communication is not intended to be a source of advertising and the recipient should always seek the advice of competent counsel licensed to practice in the recipient's country/state.

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.

Research Papers

Compendium of Research Papers
August 27, 2024

Digital Health in India
August 19, 2024

The Indian Pharmaceutical Industry
August 15, 2024

NDA Connect

Connect with us at events, 
conferences and seminars.

Deal Corner

May 01, 2012

India Venture Trust - Fund I, a scheme of IndiaVenture Trust subscribed to compulsorily convertible preference shares of Vardhman Chemtech Limited for INR 700 million

DEAL BRIEF

India Venture Trust - Fund I, a scheme of IndiaVenture Trust ("IndiaVenture") subscribed to compulsorily convertible preference shares of Vardhman Chemtech Limited for INR 700 million (~USD 14 million).

Vardhman Chemtech Limited is engaged in the business of manufacturing of bulk drugs, intermediates & fine chemicals in the isoxazoles segment of penicillin.

OUR ROLE

We, at Nishith Desai Associates, acted as legal counsel to IndiaVenture Trust for this Transaction.

Disclaimer

We expressly clarify that this communication is not a solicitation or an invitation of any sort whatsoever from Nishith Desai Associates or any of its members to create an attorney-client relationship. This communication is not intended to be a source of advertising and the recipient should always seek the advice of competent counsel licensed to practice in the recipient's country/state.

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.

Research Papers

Compendium of Research Papers
August 27, 2024

Digital Health in India
August 19, 2024

The Indian Pharmaceutical Industry
August 15, 2024

NDA Connect

Connect with us at events, 
conferences and seminars.